PLK1 is also a valuable molecular target for angiogenesis, and inhibition of its expression can inhibit the formation of new tubular structures in non-small cell lung cancer and prostate cancer, and enhance the chemotherapy sensitization of paclitaxel in cancer cells (65) (Table 1). This evidence concerns the gene PLK1 and prostate carcinoma.